•
Sep 30, 2021
Capricor Q3 2021 Earnings Report
Capricor Therapeutics reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of approximately $3.9 million, or $0.17 per share, for the three months ended September 30, 2021. The company's cash and cash equivalents totaled approximately $40.8 million as of September 30, 2021.
Cleared to proceed with Phase 3 study, known as HOPE-3, for DMD patients.
Completed enrollment of INSPIRE, a Phase 2 study randomizing 63 subjects.
Announced positive final data from the HOPE-2 trial in patients with Duchenne muscular dystrophy who were treated with CAP-1002.
Opened new research and development headquarters in San Diego, California.
Capricor
Capricor
Forward Guidance
Based on the current pipeline and operating plan, the Company’s cash position is expected to be sufficient to support operations for at least two years.